Acquire cell therapy manufacturing facility with clinical and commercial capabilitiesFurther ExacTcell platform for additional clinical trials based on successful completion of POCHighlight full year.
Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is included in the company’s total 165 million outstanding.
Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is included in the company’s total 165 million outstanding shares.The Tevogen.ai
Tevogen Bio's Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.